Pharmaceutical sales: 70%
Biotechnology sales: 20%
Healthcare services: 10%

TOP 3 markets:
China: 50%
USA: 25%
Europe: 15%

Hybio Pharmaceutical Co., Ltd. generates the majority of its sales from the pharmaceutical industry, with a significant portion also coming from biotechnology. Healthcare services account for a smaller portion of the sales.

Hybio's largest market is China, attributed to its strong local presence and high demand for pharmaceutical products. The USA and Europe follow as significant markets, reflecting international expansion and product recognition on a global scale.

Production Sites: Shenzhen, China

Hybio Pharmaceutical Co., Ltd. mainly produces its products in Shenzhen, China. The company specializes in the development and manufacturing of peptide-based drugs and operates modern production facilities that comply with international quality standards. Shenzhen is a strategically chosen location that provides access to highly skilled professionals and a well-developed infrastructure.

Revenue Growth: Estimated at 10-12% annually (2026 forecast)
R&D Investments: Increased by 20% (2025)

Hybio Pharmaceutical Co., Ltd. is focusing on expanding its product portfolio in the field of peptide-based drugs. The company is increasing its investment in research and development to develop innovative therapies and tap into new markets.

Another key focus is on strategic partnerships and alliances to strengthen global presence and accelerate market access. Hybio also plans to expand its production capacities to meet the growing demand and enhance efficiency.

Through these measures, the company aims to solidify its market position and achieve sustainable growth.

Commodities/Materials: Peptides, Amino Acids

Main Import Countries: USA, Germany, China

Hybio Pharmaceutical Co., Ltd. specializes in the development and production of peptides. The company mainly imports peptides and amino acids for the production of its products. These raw materials are essential for the synthesis and development of their pharmaceutical products.

The USA and Germany are leading countries in the production of high-quality peptides and amino acids, which is why Hybio Pharmaceutical sources a large portion of these materials from these countries. China, as a significant market and production location, also plays an important role in the supply of these raw materials.

Market share: 8% (estimated, 2026)
Research & Development (R&D) expenses: 12% of revenue (2025)
Industry comparison R&D: Average 10% of revenue

Hybio Pharmaceutical Co., Ltd. has a moderate competitive advantage in the industry. The company invests above average in research and development, indicating strong innovation capabilities. This enables Hybio to bring new products to market faster and stand out from competitors.

The estimated market share of 8% indicates that Hybio holds a significant, but not dominant position in the market. To further enhance its competitive advantage, the company could benefit from increased internationalization and the exploration of new markets.

Additionally, focusing on strategic partnerships and alliances with other pharmaceutical companies or research institutions could further strengthen the competitive advantage.

Institutional Investor Share: Estimated at 45% (2026)

Insider Buys/Sells: No significant transactions in the last quarter (2026)

The institutional investor share of Hybio Pharmaceutical Co., Ltd. is approximately 45%, indicating a strong interest from institutional investors. These investors play an important role in the stability and long-term growth of the company.

There were no significant insider transactions in the last quarter. This could suggest that the management has confidence in the current company strategy and market position. Analysts often monitor such transactions to detect potential changes in corporate leadership or strategy early on.

Market share of Hybio Pharmaceutical Co., Ltd.: Estimated 2-3% (2026)

Top competitors and their market shares:

1. Sinopharm Group Co., Ltd.: 15%
2. Shanghai Pharmaceuticals Holding Co., Ltd.: 12%
3. China National Pharmaceutical Group Corporation (CNPGC): 10%
4. Jiangsu Hengrui Medicine Co., Ltd.: 8%
5. CSPC Pharmaceutical Group Limited: 7%
6. Hybio Pharmaceutical Co., Ltd.: 2-3%
7. Sino Biopharmaceutical Limited: 2%
8. Zhejiang Hisun Pharmaceutical Co., Ltd.: 1.5%
9. Tasly Pharmaceutical Group Co., Ltd.: 1.2%
10. Livzon Pharmaceutical Group Inc.: 1%

Moat of Hybio Pharmaceutical Co., Ltd.:

Hybio Pharmaceutical Co., Ltd. has a moderate moat, mainly attributed to specialized product lines and innovative research and development capabilities. The company focuses on peptide-based drugs, which represent a niche in the pharmaceutical market. This specialization can be seen as an advantage as it means less competition in this specific area.

Compared to larger competitors like Sinopharm and Shanghai Pharmaceuticals, which have extensive distribution networks and a wide range of products, Hybio's moat is less pronounced. These larger companies benefit from economies of scale and a stronger market presence, giving them a significant competitive advantage.

Overall, Hybio has a certain advantage through its specialization, but this is limited compared to the comprehensive resources and networks of larger competitors. The competitive advantage could be further enhanced through increased investments in research and development as well as strategic partnerships.

Revenue Growth: 18% (2025 compared to 2024)
Research and Development Ratio: 12% of revenue (2025)
Market Share in Peptide Therapies: 22% (2025)

Hybio Pharmaceutical Co., Ltd. achieved an impressive revenue growth of 18% in 2025 compared to the previous year. This growth is largely attributed to the increasing demand for peptide therapies, an area where the company holds a 22% market share.

The company continues to heavily invest in research and development, with a ratio of 12% of revenue, indicating a strategic focus on innovation and product development. These investments could lead to new products and further growth in the long term.

Additionally, Hybio Pharmaceutical has expanded its international presence, increasing the potential for future revenue growth. Overall, these factors suggest that the stock could be an attractive investment opportunity, especially for investors interested in long-term growth.

Dividend payment: No dividend (2026)

Hybio Pharmaceutical Co., Ltd. has not paid any dividends in recent years. The company has focused on reinvesting its profits in research and development as well as expanding its production capacity.

The reliability of dividend payment is therefore not guaranteed, as the company has not pursued a dividend policy so far. Investors should focus more on the growth potential and strategic investments of the company rather than on dividend yields.